Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. National Institute for Health and Clinical Excellence. Questions and answers on the withdrawal of the marketing authorisation application for Belviq (lorcaserin) EMA/309180/2013 EMEA/H/C/002597. (last accessed 8 November 2013)Įuropean Medicines Agency. 001 Canada vs United Kingdom, Bonferroni P. A significantly greater percentage of MUH smokers in the United States (48.8) and Canada (44.7) than in the United Kingdom (35.8) reported completely banning smoking in their homes (United States vs United Kingdom, Bonferroni P <. Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine/topiramate, EMA/109958/2013 EMEA/H/C/002350. We observed similar differences in all 3 countries. Available at (last accessed 5 November 2013)Įuropean Medicines Agency. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.ĭepartment of Health. As new treatments for obesity are approved, their effectiveness should be measured in routine clinical practice, as effectiveness may be considerably less than seen in randomized trials.Įlectronic healthcare records obesity orlistat pharmacoepidemiology sibutramine. United Kingdom To Regress To Imperial Weights and Measures (.uk) 558 Posted by BeauHD on Friday Septem09:40PM from the ditching-the-metric-system dept. Orlistat and sibutramine had early effects on weight loss, not sustained over 3 years. Non-intervention patients had slight increases in weight throughout the 3 year period, with gains ranging between 0.01 and 0.06 kg month(-1). Patients receiving sibutramine lost, 1.28 kg month(-1) (1.26 to 1.30) over the first 4 months, but by 3 years had exceeded baseline weight. Weight gain then occurred, although weight remained slightly below baseline at 3 years. Patients receiving orlistat lost, on average, 0.94 kg month(-1) (0.93 to 0.95) over the first 4 months. We identified 100 701 patients receiving orlistat, 15 355 receiving sibutramine and 508 140 non-intervention patients, with body mass index of 37.2, 36.6 and 33.2 kg m(-2), respectively. Mean change with 95% confidence intervals (CI) was estimated. Mixed effects linear regression with splines was used to model change in weight and BMI. For comparison, we matched each patient with up to five obese patients receiving neither drug. Results: We identified 100 701 patients receiving orlistat, 15 355 receiving sibutramine and 508 140 non-intervention patients, with body mass index of 37.2, 36.6 and 33.2 kg m(-2), respectively. Mean change with 95 confidence intervals (CI) was estimated. We used United Kingdom data from the Clinical Practice Research Datalink to estimate the effects of orlistat or sibutramine on weight and BMI over 3 years following treatment initiation. Mixed effects linear regression with splines was used to model change in weight and BMI. We assessed the effects on weight and body mass index (BMI) of orlistat and sibutramine when delivered in routine primary care. Percentage values for W, H, W/H relations, and %BF by age group are provided for comparison with other population studies.Drug treatments for obesity have proven efficacy from randomized trials, but their effectiveness in routine clinical practice is unknown. In the absence of skinfold thickness measurements the W/H2 could readily be implemented during a routine medical and applied for the estimation of %BF in the offshore population provided that the appropriate regression equation were used and that the limitations of the technique are recognised. Comparison with other studies, however, would be more easily accomplished if W/H2 were used. Thus either may be used with similar levels of confidence. ![]() Little difference regarding the qualities of these two indices were detected in terms of poor correlation with height and strong correlation with weight. The significant increase in percentage body fat (%BF) with increasing age resulted in the development of age group specific regression equations relating %BF to the indices of W/H1♵ and W/H2 (body mass index or Quetelet index). The percentage body fat was estimated from skinfold thicknesses and the correlations of adiposity with the various W/H relations were evaluated. Weight and height were used to calculate W/H relations. Weight (W), height (H), and skinfold thicknesses at biceps, triceps, subscapular, and suprailiac sites were measured in a United Kingdom offshore workforce.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |